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Abstract
Background—The membrane voltage clock and calcium (Ca2+) clock jointly regulate sinoatrial
node (SAN) automaticity. VK-II-36 is a novel carvedilol analog that suppress sarcoplasmic
reticulum (SR) Ca2+ release but does not block β-receptor. The effect of VK-II-36 on SAN
function remains unclear. The purpose of this study was to evaluate whether VK-II-36 can
influence SAN automaticity through inhibiting the Ca2+ clock.
Methods and Results—We simultaneously mapped intracellular Ca2+ and membrane potential
in 24 isolated canine right atriums, using previously described criteria of the timing of late
diastolic intracellular Ca elevation (LDCAE) relative to the action potential upstroke to detect the
Ca2+ clock. Pharmacological intervention with isoproterenol (ISO), ryanodine, caffeine, and VK-
II-36 were performed after baseline recordings. VK-II-36 caused sinus rate downregulation and
reduced LDCAE in the pacemaking site under basal condition (P<0.01). ISO induced an upward
shift of the pacemaking site in SAN and augmented LDCAE in pacemaking site. ISO also
significantly and dose-dependently increased the sinus rate. The treatment of VK-II-36 (30
μmol/L) abolished both the ISO-induced shift of pacemaking site and augmentation of LDCAE
(P<0.01), and suppressed the ISO-induced increase in sinus rate (P=0.02).
Conclusions—Our results suggest that sinus rate may be partly controlled by Ca2+ clock via SR
Ca2+ release during β-adrenergic stimulation.
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The mechanism of spontaneous diastolic depolarization (DD) of sinoatrial node (SAN) cells
has traditionally been attributed to a membrane voltage clock mechanism, mediated by
voltage-sensitive membrane currents, such as the hyperpolarization-activated pacemaker
current (If) regulated by cAMP [1,2]. It was reported that ivabradine, a selective If current
inhibitor, reduces spontaneous heart rate and has cardioprotective effects [3]. Some more
recent studies implicate a complementary “Ca2+ clock” mechanism mediated by Ca2+
release from the sarcoplasmic reticulum (SR) causing DD via activation of Na/Ca exchanger
current (INCX), which coordinately regulates sinus rate along with the membrane clock [4–
6]. Recently, Himeno et al. [7] provided mathematical modeling and guinea pig single cell
data supporting the predominance of the membrane clock in regulating SAN automaticity.
Therefore, it remains unclear whether or not Ca2+ clock plays an important role in
controlling sinus rate.
Ca2+ can be released from the SR through activation of the ryanodine receptor (RyR). Under
normal conditions, the L-type Ca2+ channels are activated, leading to a small Ca2+ influx.
This Ca2+ influx then activates RyRs, resulting in a large Ca2+ release from the SR and
subsequent muscle contraction. The process is known as calcium-induced calcium release
(CICR) [8]. In addition to this depolarization-stimulated Ca2+ release, Ca2+ can also be
released spontaneously due to Ca2+ overload in the SR. When SR Ca2+ content reaches a
critical level, spontaneous SR Ca2+ release in the form of Ca2+ waves or Ca2+ oscillations
occurs in cardiac cells in the absence of membrane depolarization [9,10]. Under conditions
of SR Ca2+ overload by a variety of factors such as catecholamine or stresses, spontaneous
SR Ca2+ release occurs as a result of RyRs activation by SR luminal Ca2+ [11]. Jiang et al.
[12] referred this depolarization-independent Ca2+ overload-induced SR Ca2+ release as
store-overload-induced Ca release (SOICR). Furthermore, they reported that RyR mutations
in catecholaminergic polymorphic ventricular tachycardia (CPVT) reduce the threshold for
SOICR by increasing the sensitivity of the channel to activation by luminal Ca2+, and
enhancing the propensity for delayed afterdepolarizations and triggered arrhythmias under
conditions of SR Ca2+ overload [13]. CPVT is typically associated with sinus bradycardia
[14,15]. We reported in previous publications that spontaneous SR Ca release is important in
the SAN automaticity during β-adrenergic stimulation, and it acts synergistically with
activation of membrane ionic currents such as If to accelerate the sinus rate in intact canine
SAN [16–19].
Recently, Zhou et al. [20] demonstrated that carvedilol suppressed SOICR independently of
its β-blocking effect and prevented CPVT in RyR mutant mice. VK-II-36 is a carvedilol
analog that does not significantly block β receptor. We demonstrated that VK-II-36 could
suppress ventricular arrhythmias by inhibiting triggered activities [21]. Because SAN
activity may share mechanisms underlying both automaticity and triggered activity [22], we
hypothesize that SAN treated with VK-II-36 could reduce spontaneous SR Ca release,
leading to suppressed SAN automaticity. In this study, we performed dual optical mapping
of transmembrane potential (Vm) and intracellular Ca2+ (Cai) with intact canine RAs. We
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studied the effects of VK-II-36 on sinus rate at baseline and during β-adrenergic stimulation
to test that hypothesis.
Materials and Methods
Langendorff-perfused canine SAN preparation
This study protocol was approved by the Institutional Animal Care and Use Committee of
Indiana University School of Medicine and the Methodist Research Institute, and conforms
to the guidelines of the American Heart Association. We studied isolated canine RAs in 24
mongrel dogs (22 to 28 kg). The heart was rapidly excised under general anesthesia and the
right coronary artery was perfused with 37°C Tyrode’s solution equilibrated with 95% O2
and 5% CO2 to maintain a pH of 7.4. The composition of Tyrode’s solution was (in
mmol/L): 125 NaCl, 4.5 KCl, 0.25 MgCl2, 24 NaHCO3, 1.8 NaH2PO4, 1.8 CaCl2, and 5.5
glucose). The coronary perfusion pressure was regulated between 50 and 60 mmHg. To
ensure adequate atrial perfusion, all ventricular coronary branches were tied off. Both
ventricles and left atrium were removed. Because SAN is subepicardial in dogs [24], we
mapped the epicardial side of the tissue. The SAN area was typically located posterior to the
sulcus terminalis. Contractility was inhibited by 10 – 17 μmol/L of blebbistatin, and the
motion artifact was negligible even after isoproterenol (ISO) infusion. Pseudo-ECG was
recorded with widely spaced bipolar RA electrodes using ISO-DAM8A (World precision
instruments, FL, USA).
Dual Vm and Cai recordings
Optical mapping analysis was performed as previously described [25]. The hearts were
stained with Rhod-2 AM and RH237 (Molecular Probes) and excited with laser light at 532
nm. Fluorescence was collected using 2 cameras (MiCAM Ultima, BrainVision, Tokyo,
Japan) at 1 ms/frame and 100 × 100 pixels with spatial resolution of 0.35 × 0.35 mm2/pixel.
After mapping baseline spontaneous beats, pharmacologic intervention was performed in 24
isolated canine RAs. At first, the VK-II-36 dose response (1 to 30 μmol/L) was evaluated on
SAN and surrounding RA (n=5). Next, we determined the ISO dose response (0.01 to 1.0
μmol/L) of SAN function under basal condition (n=5), and examined the response against
ISO during 30 μmol/L VK-II-36 infusion (n=4). Furthermore, we examined the effects of
ryanodine, RyR inhibitor, to SAN function. In 4 dogs, the ryanodine dose response (0.1 to
10 μmol/L) of sinus rate was evaluated. In the same dogs, we also determined the ISO dose
response of sinus rate during 3 μmol/L ryanodine infusion. To identify effects of caffeine on
SAN automaticity, which triggers Ca2+ release by activating RyR, caffeine (20 mmol/L, 2
mL) was given as a bolus injection into the coronary artery within 1 second (n=3). In 3 dogs,
we examined whether or not the pretreatment of VK-II-36 (30 μmol/L) influences against
the effects of caffeine on SAN automaticity. The synthesis of VK-II-36 is described in our
previous paper [21].
Data Analysis
Sinus rate was defined as the rate generated by SAN activations confirmed with optical
mapping. The Cai and Vm traces were normalized to their respective peak-to-peak amplitude
for comparison of timing and morphology. The slopes of late diastolic intracellular Ca
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elevation (LDCAE) were measured from the onsets of LDCAE and to peak levels of
LDCAE. The onsets of LDCAE were defined by the time of the transition between negative
to positive values in dCai/dt curves [16]. Student’s t-tests were used to compare means
between two groups. One-way analyses of variance followed by Bonferroni-Dunn test were
used to compare three or more groups. Data were presented as mean ± SEM. A P-value of
<0.05 was considered statistically significant.
The authors had full access to and take full responsibility for the integrity of the data. All
authors have read and agree to the manuscript as written.
Results
Effect of a SOICR blocker, VK-II-36, on SAN function
The averaged basal sinus rate of intact canine SAN used in the present study was 101±4
bpm (range 82 – 132 bpm, n=24). Figure 1 shows changes in sinus rate after the treatment of
VK-II-36 or ryanodine. Both VK-II-36 and ryanodine significantly and dose-dependently
decreased sinus rate. Figure 2 shows the change of activation pattern in SAN and the
surrounding RA by VK-II-36. Figure 2b represents an example of the activation pattern on
SAN and surrounding RA during spontaneous sinus rhythm. Under basal conditions, the
pacemaking sites were located in the middle SAN. The upstrokes of Cai and Vm were nearly
simultaneous. Small amplitude LDCAEs in pacemaking site were observed in the middle
SAN at baseline recording in all preparations (arrows in Figure 2b, range 0.82 – 2.49 AU/s,
n=24). The treatment of VK-II-36, which blocks SOICR, resulted in a downward (caudal)
shift of the pacemaking site to lower SAN (Figure 2c, n=5). VK-II-36 infusion made
LDCAE disappearance in the pacemaking site (dotted line arrow in Figure 2c). Figure 2d
shows that VK-II-36 reduced LDCAE dose-dependently (P<0.01).
Effects of VK-II-36 on SAN function in the presence of β-adrenergic stimulation
ISO infusion significantly increased sinus rate, while the pretreatment of VK-II-36 or
ryanodine reduced this ISO effect (Figure 3a). ISO (1.0 μmol/L)-induced increase in heart
rate was significantly suppressed by VK-II-36 (30 μmol/L, P=0.02) or ryanodine (3 μmol/L,
P=0.007) (Figure 3b). Figure 4 shows the effect of VK-II-36 on ISO-induced activation
pattern change. ISO infusion resulted in an upward (cranial) shift of the pacemaking site
(Figure 4a), coincident with the appearance of robust LDCAEs (arrows in Figure 4a). Figure
4b shows the impact of β-adrenergic stimulation on the SAN function after 30 μmol/L VK-
II-36 treatment. VK-II-36 treatment inhibited ISO-induced upward shifting of the
pacemaking site and the augmentation of LDCAE (Figure 4b). Figure 4c shows the distance
of upward shifting of the pacemaking site dose-dependently when ISO infusion was
increased from 0.01 to 1.0 μmol/L. VK-II-36 pretreatment almost completely inhibited ISO-
induced upward shifting of the leading pacemaker site (ISO 1.0 μmol/L: 5.9 ± 0.3 (VK-,
n=5) vs. 0.8 ± 0.1 mm (VK+, n=4), P<0.01, Figure 4c). ISO also dose-dependently
augmented LDCAE. When ISO infusion was 1.0 μmol/L, the slope of LDCAE increased to
4.5±0.3 AU/s. VK-II-36 treatment significantly inhibited ISO-induced augmentation of
LDCAE (1.0±0.2 AU/s, P<0.01, Figure 4d).
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Effects of VK-II-36 on caffeine-induced changes in sinus node automaticity
Caffeine sensitizes RyRs to activation, resulting in increased SR Ca2+ release. We examined
whether or not the treatment of VK-II-36 (30 μmol/L) suppress the effects of caffeine on
SAN automaticity (Figure 5). When a 2-mL caffeine bolus (20 mmol/L) was injected
directly into the right coronary artery, the pacemaking site was soon shifted to upward, and
sinus rate increased from 95.0 ± 8.5 to 158.0 ± 5.0 bpm (P=0.001). Caffeine enhanced the
slope of LDCAE in the pacemaking site from 1.2 ± 0.1 to 4.8 ± 0.3 AU/s (P<0.001). The
treatment of VK-II-36 (30 μmol/L) did not inhibit caffeine-induced shifting of pacemaking
site, sinus rate increase (152.7 ± 7.7 vs. 158.0 ± 5.0 bpm, P=0.59, Figure 5C), or LDCAE
augmentation (4.2 ± 0.3 vs. 4.8 ± 0.3 AU/s, P=0.21, Figure 5D).
Discussion
The main findings of the present study are as follows. 1) A carvedilol analogue VK-II-36, a
SOICR inhibitor, dose-dependently decreased sinus rate as with ryanodine treatment, and
reduced LDCAE in the pacemaking site. 2) ISO induced an upward shift of the pacemaking
site, coincident with the appearance of robust LDCAE. Sinus rate increased dose-
dependently. Treatment with VK-II-36 reduced the ISO-induced effects on SAN function. 3)
Caffeine also induced upward shift of the pacemaking site, coincident with the appearance
of robust LDCAE, and increased sinus rate. Interestingly, the effects of caffeine were not
inhibited by VK-II-36 treatment. These findings support the importance of spontaneous SR
Ca2+ release (SOICR) for the pacemaker function in the intact canine SAN, especially
during β-adrenergic stimulation.
This is the first report demonstrating that SOICR is involved in the increase of sinus rate, the
shift of pacemaking site in SAN, and the augmentation of LDCAE at the pacemaking site
during β-adrenergic stimulation. It has still been discussed whether Ca2+ clock or membrane
clock plays a dominant role in SAN automaticity. Vinogradova et al. [4] reported that
positive chronotropic effect of β-adrenergic stimulation is the result of increase in the Ca2+
transient caused by β-adrenergic stimulation, because they observed that the chronotropic
effect in isolated SAN cells from rabbit is abolished or greatly reduced after the suppression
of the Ca2+ transient by ryanodine. On the other hand, Honjo et al. [26] reported that SR
Ca2+ release does not play a dominant role in pacemaker function in SAN, because
ryanodine, which disables the SR Ca2+ release channel, did not abolish spontaneous activity
in SAN. Our laboratory reported that ryanodine prevented ISO-induced LDCAE and blunted
sinus rate acceleration, and that If blockade with ZD 7288 modestly blunted but did not
prevent LDCAE or sinus rate acceleration by ISO in the intact canine dog [16]. Furthermore,
the present study demonstrates that spontaneous SR Ca2+ release inhibition via SOICR
blockade by VK-II-36 prevented ISO-induced upward shift of the pacemaking site in SAN
and augmentation of LDCAE, and blunted sinus rate acceleration, which is similar to the
effect of ryanodine. Our results suggest that sinus rate may be partly controlled by Ca2+
clock via SOICR during β-adrenergic stimulation. We demonstrated that SR Ca2+ release
inhibition by ryanodine suppressed sinus rate both under basal condition and during β-
adrenergic stimulation. SOICR inhibition by VK-II-36 also significantly decreased sinus rate
with LDCAE reduction which indicates inhibition of spontaneous SR Ca2+ release. These
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results suggest that SOICR is an important factor for SAN automaticity, especially during β-
adrenergic stimulation.
VK-II-36 treatment shifted the pacemaking site to downward both under baseline condition
and during β-adrenergic stimulation. It suggests that VK-II-36 is more effective in the
superior SAN than the inferior SAN. The mechanism may be explained by the heterogeneity
of SAN [27]. The key protein regulator of Ca uptake is phospholamban (PLB), which
inhibits SERCA2a in its dephosphorylated state. β-adrenergic stimulation phosphorylates
PLB, relieving its inhibition of SERCA2a and increasing Ca2+ uptake. As a result,
spontaneous SR Ca2+ release occurs as a result of activation of the RyR channel by SR
luminal Ca2+. We previously reported that the SERCA2a/PLB molar ratio at SAN sites was
significantly lower than at RA sites, and not significant but tends to be lower in superior
SAN than in inferior SAN in canine hearts [16]. These may be involved in the
heterogeneous effect to SAN function by SOICR inhibition.
β-adrenergic stimulation increases spontaneous SR Ca2+ release. Under conditions in which
the SR Ca2+ content is abruptly increased, such as exercise, emotional stress, or on the
infusion of cathecholamines, β-adrenergic receptors are activated, leading to activation of
PKA, which in turn phosphorylates the L-type Ca2+ channel and PLB. This PKA
phosphorylation increases both Ca2+ influx and SR Ca2+ uptake, resulting in an abrupt
increase on SR free Ca2+. The resulting SR Ca2+ spillover can activate the Na/Ca2+
exchanger, leading to increase of sinus rate. VK-II-36 inhibits SOICR. However, the
detailed mechanism of VK-II-36-induced effect has yet to be determined. Jiang et al. [12]
reported that CPVT RyR mutations enhance SOICR by increasing the channel sensitivity to
activation by luminal Ca2+, and alterations in RyR function are likely to contribute to the
reduced threshold for SOICR, resulting in the high incidence of DAD-associated ventricular
tachycardia. Our results could suggest that VK-II-36 inhibits spontaneous SR Ca2+ release
by increasing the threshold for luminal Ca2+ activation of RyR. VK-II-36 inhibited ISO-
induced effects in canine intact SAN, but did not inhibit caffeine-induced effects. Kong et al.
[28] reported that caffeine triggers Ca2+ release by reducing the threshold for luminal Ca2+
activation of RyR. The present results suggest that caffeine reduced the threshold for
luminal Ca2+ activation elevated by VK-II-36 and might cancel out the VK-II-36-induced
inhibitory effect on SR Ca2+ release. As a result of that, caffeine shifted the leading
pacemaker site to upward in SAN and augmented LDCAE at the pacemaking site, and
increased sinus rate despite VK-II-36 treatment.
Another carvedilol analogue, VK-II-86, is known to have no effects on heart rate in either
wild type or R4496C-heterozygous mice [20]. In comparison, VK-II-36 significantly
reduced sinus rate in canine hearts. The mechanisms by which VK-II-36 exhibits differential
effects in mice and canine SA nodes are unclear. One possibility is that the mice sinus node,
which operates at an intrinsic rate many times faster than that of the canine sinus node, does
not depend on the calcium release from the ryanodine receptor for heart rate control.
However, such a view is not congruent with experimental results showing that calcium
homeostasis in mouse SA node also plays an active role in heart rate acceleration (29).
Alternatively, the ryanodine receptor in the mice sinus nodes may be less sensitive to VK
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compound than the ryanodine receptors in canine sinus node. Further studies are required to
test these hypotheses.
Limitations
There are several limitations in the present study. Firstly, we did not directly measure the SR
Ca2+ release. It is therefore possible that some components of LDCAE might have
originated from the membrane Ca2+ currents. However, we think LDCAE was originated
from the SR Ca2+ release, because LDCAE was suppressed by VK-II-36 that reduced SR
function via SOICR blocking effect. Secondly, VK-II-36 agent is a carvedilol analog that
blocks SOICR but does not block β receptor. However, the other effects cannot be excluded.
Yokoyama et al. [30] reported carvedilol inhibits the Ca current, delayed rectifier K+ current
and hyperpolarization-activated inward current in the SAN cells with voltage clamp
experiments. VK-II-36 may have the same effects, and cause a suppression of spontaneous
pacemaker activity by the inhibition of various currents. Thirdly, the blebbistatin used for
inhibiting cardiac contractility is an excitation-contraction uncoupling drug, and may
influence the intracellular Ca dynamics. Fedorov et al. [24] reported that blebbistatin
increased resting fluorescence by 39%. We cannot rule out the possibility that the
blebbistatin may influence our data and the interpretation of the results. Fourthly, we
reported that LDCAE were observed in only 4 of 25 preparations in the previous paper [16].
The exact reason why the appearance of LDCAE in this study is different from the previous
paper is unclear. It might be attributed to improved experimental technique and data quality,
allowing better detection of small LDCAE in this study.
Conclusions
In conclusion, SOICR is important for SAN automaticity. Sinus rate might be partly
controlled by Ca2+ clock via SOICR during β-adrenergic stimulation. Spatial heterogeneity
of SOICR may be a key in determining the site of dominant pacemaker. Further studies on
SOICR may lead to the development of novel treatments for SAN dysfunction.
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Figure 1. The effect of SR Ca release inhibitor on intact SAN
a, Changes of sinus rate by VK-II-36 or ryanodine infusion. b, Sinus rate at 30 μmol/L VK-
II-36 or 10 μmol/L ryanodine infusion. VK = VK-II-36; Ryd = ryanodine.
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Figure 2. The change of activation pattern of SAN by SR Ca release inhibitor, VK-II-36
a, Photo of the isolated RA preparation showing the SAN and surrounding RA. b, Activation
pattern of the SAN and surrounding RA under basal condition. The color picture shows
isochronal map of Vm propagation. The Cai (red) and Vm (black) recordings from the
superior (S), middle (M), and inferior (I) SAN are presented. Arrows point to late diastolic
Cai elevation (LDCAE). c, Activation pattern of SAN and surrounding RA during VK-II-36
infusion of 20 μmol/L. Dotted arrows point to no LDCAE. d, Effect of VK-II-36 (0 to 30
μmol/L) on the slope of LDCAE. SVC = superior vena cava; RAA = right atrial appendage.
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Figure 3. The effect of SR Ca release inhibitor to isoproterenol-induced SAN function change
a, Effects of VK-II-36 or ryanodine on isoproterenol-induced sinus rate change. b, Sinus rate
at 1.0 μmol/L isoproterenol infusion with VK-II-36 (30 μmol/L) or ryanodine (3 μmol/L).
ISO = isoproterenol; VK = VK-II-36; Ryd = ryanodine.
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Figure 4. Effect of isoproterenol on activation pattern of SAN during VK-II-36 treatment
a, Isoproterenol (1.0 μmol/L) -induced activation pattern of SAN. Color picture shows
isochronal map of Vm. The Cai (red) and Vm (black) recordings from the superior (S),
middle (M), and inferior (I) SAN are presented. Arrows point to late diastolic Cai elevation
(LDCAE). b, Effect of VK-II-36 (30 μmol/L) treatment to Isoproterenol (1.0 μmol/L) -
induced activation pattern of SAN. c, Distance of shift to upward by isoproterenol infusion
with VK-II-36 (30 μmol/L) treatment or not. d, Slope of LDCAE by isoproterenol infusion
with VK-II-36 (30 μmol/L) or not. ISO = isoproterenol; VK = VK-II-36.
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Figure 5. Effect of caffeine on activation pattern of SAN during VK-II-36 treatment
a, Caffeine (20 mmol/L, 2-mL bolus given within 1 sec)-induced activation pattern of SAN.
Color picture shows isochronal map of Vm. The Cai (red) and Vm (black) recordings from
the superior (S), middle (M), and inferior (I) SAN are presented. Arrows point to late
diastolic Cai elevation (LDCAE). b, Effect of VK-II-36 (30 μmol/L) treatment to Caffeine-
induced activation pattern of SAN. Arrows point to LDCAE. c, Sinus rate change by
caffeine infusion with VK-II-36 (30 μmol/L) treatment or not. d, Slope of LDCAE by
caffeine infusion with VK-II-36 (30 μmol/L) treatment or not. VK = VK-II-36.
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